Skip to content
value.today

Allena Pharmaceuticals, Inc.

🇺🇸 Newton, Massachusetts, USAPharmaceuticalsFounded 2011
Total raised
$80 M
3 rounds on record
Latest round
$4 M
May 2022
First round on record
Oct 2014
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Allena Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2022$4 MNo. 3$2 to $10 million

Allena Pharmaceuticals, Inc.: Raise no. 3, May 2022

Investors in this round

5 investors had bought by the notice of May 17, 2022: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Allena Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$314,771
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Louis Brenner, M.D. · Executive Officer, Director
  • Richard D. Katz, M.D. · Executive Officer
  • Alexey D. Margolin · Director
  • Allene D. Diaz · Director
  • Ann C. Miller · Director
  • Gino D. Santini · Director
  • Mark C. Fitzpatrick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “H.C. Wainwright & Co., LLC received the above sales commission and the warrants in connection with the private placement and a concurrent registered direct offering by the Issuer, which is not reported on this Form D.”
  • On the amounts: “Includes warrants to buy up to 22,438,575 shares of common stock at an exercise price of $0.1694/share issued to the investor and up to 1,256,561 shares of common stock at an exercise price of $0.20/share issued to H.C.Wainwright&Co.LLC and its affiliates”

Signed by Louis Brenner, M.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 17, 2022. Read the notice at the SEC.

optionsSEC
Nov 2015$51 MNo. 2$50 to $250 million

Allena Pharmaceuticals, Inc.: Raise no. 2, Nov 2015

Investors in this round

8 investors had bought by the notice of Dec 10, 2015: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Allena Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$51 M of $53 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexey Margolin · Executive Officer, Director
  • Louis Brenner · Executive Officer
  • Axel Bolte · Director
  • Gino Santini · Director
  • James Topper · Director
  • Robert Tepper · Director
  • Stephen Kraus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alexey Margolin, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 10, 2015. Read the notice at the SEC.

equitySEC
Oct 2014$25 MNo. 1$10 to $50 million

Allena Pharmaceuticals, Inc.: Raise no. 1, Oct 2014

Investors in this round

7 investors had bought by the notice of Nov 13, 2014: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Allena Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $27 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexey Margolin · Executive Officer, Director
  • Gino Santini · Director
  • James Topper · Director
  • Robert Tepper · Director
  • Stephen Kraus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alexey Margolin, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 13, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Allena Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (May 2022).

    SEC Form D · May 2022

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · May 2022

That is all the official record says: Allena Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

13 named in official filings. Open an investor to see everything it has backed.

Investors in Allena Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Bessemer Venture Partners VII Institutional L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Bessemer Venture Partners VII L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2017)SEC Form 3
BVP VII Special Opportunity Fund LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Deer VII & Co. L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Deer VII & Co. Ltd.Companynot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2017)SEC Form 3
FHM VI, L.L.C.Othernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
FHM VI, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Frazier Healthcare VI, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Hadley Harbor Master Investors (Cayman) L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
HBM BioCapital II LPFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Third Rock Ventures GP II, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Third Rock Ventures II, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2017)SEC Form 3
TRV GP II, LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Allena Pharmaceuticals, Inc.
NameRoleNamed in
Louis Brenner, M.D.Executive officerMay 2022
Richard D. Katz, M.D.Executive officerMay 2022
Alexey MargolinExecutive officerDec 2015
Louis BrennerExecutive officerDec 2015
Alexey D. MargolinDirectorMay 2022
Allene D. DiazDirectorMay 2022
Ann C. MillerDirectorMay 2022
Gino D. SantiniDirectorMay 2022
Louis Brenner, M.D.DirectorMay 2022
Mark C. FitzpatrickDirectorMay 2022
Alexey MargolinDirectorDec 2015
Axel BolteDirectorDec 2015
Gino SantiniDirectorDec 2015
James TopperDirectorDec 2015
Robert TepperDirectorDec 2015
Stephen KrausDirectorDec 2015